{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:48:26Z","timestamp":1782316106936,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Ampullary adenocarcinoma (AAC) is rare. Five-year survival rates of 30% to 70% are seen after resection. This broad range of survival could be explained by the morphologic heterogeneity in the 3 subtypes of AAC (pancreatobiliary, intestinal, and mixed subtype), which complicates the prediction of individual prognosis and clinical decision making with regard to adjuvant therapy. To date, there are no prospective studies to elucidate whether adjuvant chemotherapy improves survival in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The ADAPTA study is a phase II prospective single-arm multicenter cohort study including 200 patients with resected AAC (100 patients with intestinal subtype, and 100 with pancreatobiliary- and mixed subtype). All patients will be treated with CAPOX\/ FOLFIRINOX, respectively. Outcomes will be compared after propensity score matching to the data of all patients in consecutive participating centers not treated according to the proposed regime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This pioneering prospective study aims to generate evidence on the impact of adjuvant chemotherapy tailored to the histopathologic subtypes of AAC. The outcomes of this trial could lead to changes in clinical guidelines or pave the way for future randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT06068023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000001271","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:08Z","timestamp":1773273608000},"page":"342-349","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant Chemotherapy After Curative Intent Resection of Ampullary Cancer (ADAPTA)"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2479-2092","authenticated-orcid":false,"given":"Bas A.","family":"Uijterwijk","sequence":"first","affiliation":[{"name":"Department of Surgery, Fondazione Poliambulanza"},{"name":"Department of Surgery, Amsterdam UMC"},{"name":"Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.L.","family":"Lemmers","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fondazione Poliambulanza"},{"name":"Department of Surgery, Amsterdam UMC"},{"name":"Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorine S.","family":"Klei","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fondazione Poliambulanza"},{"name":"Department of Surgery, Amsterdam UMC"},{"name":"Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Wilmink","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, University of Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione Poliambulanza, Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Millella","sequence":"additional","affiliation":[{"name":"Department of Engineering for Innovation Medicine (DIMI), Section of Innovation Biomedicine - Oncology Area, University of Verona and Verona University and Hospital Trust (AOUI)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Luchini","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maisonneuve","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, IEO European Institute of Oncology IRCCS, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[{"name":"Department of Surgery, Amsterdam UMC"},{"name":"Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abu Hilal","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fondazione Poliambulanza"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"R1-20260624","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/jso.21374","article-title":"Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER program","volume":"100","author":"Albores-Saavedra","year":"2009","journal-title":"J Surg Oncol"},{"key":"R2-20260624","doi-asserted-by":"crossref","first-page":"112","DOI":"10.14694\/EdBook_AM.2014.34.112","article-title":"Ampullary cancer: an overview","volume":"34","author":"Ahn","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R3-20260624","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1097\/PAS.0b013e31826399d8","article-title":"Ampullary region carcinomas","volume":"36","author":"Adsay","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R4-20260624","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0039-6109(05)70142-0","article-title":"Periampullary cancers","volume":"81","author":"Sarmiento","year":"2001","journal-title":"Surg Clin North Am"},{"key":"R5-20260624","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hpb.12078","article-title":"2564 resected periampullary adenocarcinomas at a single institution: trends over three decades","volume":"16","author":"He","year":"2014","journal-title":"HPB"},{"key":"R6-20260624","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11605-009-1080-7","article-title":"Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis","volume":"14","author":"Winter","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"R7-20260624","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/SLA.0000000000003177","article-title":"Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma: international multicenter cohort study","volume":"272","author":"Moekotte AL","year":"2020","journal-title":"Ann Surg"},{"key":"R8-20260624","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s11605-018-3797-7","article-title":"Immunohistochemical predictors for intestinal and pancreatobiliary types of adenocarcinoma of the ampulla of Vater","volume":"22","author":"da Silveira Santos","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"R9-20260624","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0016-5085(00)70243-5","article-title":"Abraham Vater of the ampulla (papilla) of Vater","volume":"118","author":"Lerch","year":"2000","journal-title":"Gastroenterology"},{"key":"R10-20260624","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.surg.2006.04.006","article-title":"Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up","volume":"140","author":"Riall","year":"2006","journal-title":"Surgery"},{"key":"R11-20260624","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.humpath.2013.05.003","article-title":"Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry","volume":"44","author":"Kumari","year":"2013","journal-title":"Hum Pathol"},{"key":"R12-20260624","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2407-8-170","article-title":"Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma","volume":"8","author":"Westgaard","year":"2008","journal-title":"BMC Cancer"},{"key":"R13-20260624","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","article-title":"Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma","volume":"29","author":"Yachida","year":"2016","journal-title":"Cancer Cell"},{"key":"R14-20260624","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/modpathol.2016.124","article-title":"Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases","volume":"29","author":"Reid","year":"2016","journal-title":"Modern Pathol"},{"key":"R15-20260624","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejso.2022.10.001","article-title":"Impact of histopathological type on the prognosis of ampullary carcinoma: a systematic review and meta-analysis","volume":"49","author":"Shin","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"suppl","key":"R16-20260624","doi-asserted-by":"crossref","first-page":"e15703","DOI":"10.1200\/JCO.2017.35.15_suppl.e15703","article-title":"Prognostic factors and effects of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience","volume":"35","author":"Jin","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"R18-20260624","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.pan.2020.01.009","article-title":"Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study","volume":"20","author":"Bolm","year":"2020","journal-title":"Pancreatology"},{"key":"R19-20260624","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/bjs.11555","article-title":"Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study","volume":"107","author":"Moekotte AL","year":"2020","journal-title":"Br J Surg"},{"key":"R20-20260624","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"R21-20260624","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"R22-20260624","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs Gemcitabine as adjuvant therapy for pancreatic cancer","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"R23-20260624","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","volume":"27","author":"Overman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R24-20260624","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"R26-20260624","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1245\/s10434-011-2117-1","article-title":"Carcinoma of the Ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy","volume":"19","author":"Palta","year":"2012","journal-title":"Ann Surg Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:02:33Z","timestamp":1782313353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001271"}},"subtitle":["Study Protocol for a Pan-European Prospective Multicenter Double Single Arm Trial"],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001271","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"value":"0277-3732","type":"print"},{"value":"1537-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}